Skye Bioscience, Inc. (SKYE)
USD 1.4
(-2.1%)
USD 1.4
(-2.1%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 14.07 Million USD | 16.12% |
| 2022 | 12.11 Million USD | 203.67% |
| 2021 | 3.99 Million USD | 79.7% |
| 2020 | 2.22 Million USD | 53.31% |
| 2019 | 1.44 Million USD | -91.73% |
| 2018 | 17.51 Million USD | 1190.76% |
| 2017 | 1.35 Million USD | -23.5% |
| 2016 | 1.77 Million USD | -41.64% |
| 2015 | 3.04 Million USD | 279.11% |
| 2014 | 801.89 Thousand USD | 340.23% |
| 2013 | 182.15 Thousand USD | 4111.63% |
| 2012 | 4325.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 14.45 Million USD | -9.4% |
| 2024 Q1 | 15.95 Million USD | 13.36% |
| 2023 FY | 14.07 Million USD | 16.12% |
| 2023 Q4 | 14.07 Million USD | 1.17% |
| 2023 Q2 | 10.02 Million USD | 7.02% |
| 2023 Q1 | 9.36 Million USD | -22.7% |
| 2023 Q3 | 13.9 Million USD | 38.74% |
| 2022 Q4 | 12.11 Million USD | 96.94% |
| 2022 Q2 | 5.26 Million USD | 24.35% |
| 2022 Q1 | 4.23 Million USD | 6.18% |
| 2022 FY | 12.11 Million USD | 203.67% |
| 2022 Q3 | 6.15 Million USD | 16.79% |
| 2021 FY | 3.99 Million USD | 79.7% |
| 2021 Q3 | 3.42 Million USD | 6.38% |
| 2021 Q1 | 2.92 Million USD | 31.48% |
| 2021 Q2 | 3.21 Million USD | 10.17% |
| 2021 Q4 | 3.99 Million USD | 16.61% |
| 2020 FY | 2.22 Million USD | 53.31% |
| 2020 Q4 | 2.22 Million USD | -11.03% |
| 2020 Q3 | 2.49 Million USD | -24.85% |
| 2020 Q2 | 3.32 Million USD | 39.81% |
| 2020 Q1 | 2.37 Million USD | 64.0% |
| 2019 Q3 | 18.12 Million USD | 23.14% |
| 2019 Q1 | 32.58 Million USD | 86.02% |
| 2019 FY | 1.44 Million USD | -91.73% |
| 2019 Q2 | 14.72 Million USD | -54.83% |
| 2019 Q4 | 1.44 Million USD | -92.01% |
| 2018 Q4 | 17.51 Million USD | 54.75% |
| 2018 FY | 17.51 Million USD | 1190.76% |
| 2018 Q3 | 11.32 Million USD | 10.05% |
| 2018 Q2 | 10.28 Million USD | 15.43% |
| 2018 Q1 | 8.91 Million USD | 556.61% |
| 2017 Q4 | 1.35 Million USD | -44.56% |
| 2017 Q1 | 1.84 Million USD | 4.07% |
| 2017 Q2 | 2.26 Million USD | 22.5% |
| 2017 Q3 | 2.44 Million USD | 8.24% |
| 2017 FY | 1.35 Million USD | -23.5% |
| 2016 Q4 | 1.77 Million USD | 3.68% |
| 2016 FY | 1.77 Million USD | -41.64% |
| 2016 Q1 | 3.35 Million USD | 10.51% |
| 2016 Q2 | 1.33 Million USD | -60.22% |
| 2016 Q3 | 1.71 Million USD | 28.03% |
| 2015 Q2 | 1.68 Million USD | 108.38% |
| 2015 Q4 | 3.04 Million USD | -13.52% |
| 2015 Q3 | 3.51 Million USD | 109.02% |
| 2015 Q1 | 807.08 Thousand USD | 0.65% |
| 2015 FY | 3.04 Million USD | 279.11% |
| 2014 Q3 | 349.5 Thousand USD | 304.13% |
| 2014 Q4 | 801.89 Thousand USD | 129.44% |
| 2014 Q1 | 49.34 Thousand USD | -8.34% |
| 2014 FY | 801.89 Thousand USD | 340.23% |
| 2014 Q2 | 86.48 Thousand USD | 75.26% |
| 2013 Q2 | 64.24 Thousand USD | -6.59% |
| 2013 Q4 | 53.83 Thousand USD | -13.6% |
| 2013 FY | 182.15 Thousand USD | 4111.63% |
| 2013 Q3 | 62.31 Thousand USD | -3.0% |
| 2013 Q1 | 68.78 Thousand USD | 0.0% |
| 2012 Q3 | 4325.00 USD | 0.0% |
| 2012 FY | 4325.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -51196.719% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -48.662% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 80.582% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1639.903% |
| Rebus Holdings, Inc. | 5.24 Million USD | -168.452% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 76.154% |
| Qrons Inc. | 1.48 Million USD | -845.261% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -1047.617% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 81.217% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -31384.314% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 73.601% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -46.861% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -3238.069% |
| SQZ Biotechnologies Company | 50.03 Million USD | 71.877% |
| Intellipharmaceutics International Inc. | 12 Million USD | -17.183% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -265.377% |
| Mesoblast Limited | 188.44 Million USD | 92.532% |
| Marizyme, Inc. | 26.67 Million USD | 47.247% |
| Genus plc | 485 Million USD | 97.099% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -140.855% |
| Pharming Group N.V. | 244.07 Million USD | 94.234% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -600.066% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -459.237% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -270.322% |
| ContraFect Corporation | 32.53 Million USD | 56.742% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -610.249% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -267.647% |
| IMV Inc. | 37.93 Million USD | 62.902% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -19.477% |
| MultiCell Technologies, Inc. | 1617.67 USD | -869807.274% |
| ONE Bio Corp. | 27.49 Million USD | 48.82% |
| Accustem Sciences Inc. | 1.07 Million USD | -1203.903% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 81.823% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -565.332% |
| Q BioMed Inc. | 8.13 Million USD | -73.028% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 83.032% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -173.458% |
| Biomind Labs Inc. | 1.49 Million USD | -839.018% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 88.147% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -55.628% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 23.535% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -881.422% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -9803.395% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -6897.071% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -144.912% |
| GB Sciences, Inc. | 5.41 Million USD | -159.752% |
| Alpha Cognition Inc. | 7.16 Million USD | -96.409% |
| HST Global, Inc. | 593.59 Thousand USD | -2270.686% |
| CSL Limited | 18.62 Billion USD | 99.924% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -1017.559% |
| Halberd Corporation | 728.71 Thousand USD | -1831.091% |
| Enzolytics Inc. | 365.26 Million USD | 96.147% |
| Agentix Corp. | 2.51 Million USD | -460.523% |
| Resverlogix Corp. | 67.39 Million USD | 79.12% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1577.798% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 96.837% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -721.017% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 43.133% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -18.223% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -283.945% |
| AVAX Technologies, Inc. | 3.99 Million USD | -252.357% |
| Zenith Capital Corp. | 27.56 Thousand USD | -50943.669% |
| Genscript Biotech Corporation | 1.32 Billion USD | 98.939% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -5796.498% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -276.837% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1966.91% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -418.956% |
| Kadimastem Ltd | 3.5 Million USD | -301.505% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -20925.608% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 72.003% |
| BioStem Technologies, Inc. | 15.9 Million USD | 11.521% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -2928.246% |
| LadRx Corporation | 2.2 Million USD | -539.493% |
| Cell Source, Inc. | 15.8 Million USD | 10.973% |
| Regen BioPharma, Inc. | 5.45 Million USD | -157.846% |
| Regen BioPharma, Inc. | 5.45 Million USD | -157.846% |
| NovAccess Global Inc. | 7.86 Million USD | -79.019% |
| Affymax, Inc. | 8.87 Million USD | -58.632% |
| Itoco Inc. | 1.65 Million USD | -751.237% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -585.927% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -132.637% |
| Mobile Lads Corp. | 1.31 Million USD | -971.356% |
| CytoDyn Inc. | 127.89 Million USD | 88.997% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -33566.425% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -798.393% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -27.405% |
| SYBLEU INC | 681.41 Thousand USD | -1965.154% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -130.62% |
| International Stem Cell Corporation | 5.27 Million USD | -166.671% |
| Bioxytran, Inc. | 3.24 Million USD | -333.058% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -2148.646% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -204.783% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 65.674% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 36.797% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -594.792% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -156.886% |
| Neutra Corp. | 973.52 Thousand USD | -1345.486% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 51.5% |
| PureTech Health plc | 125.58 Million USD | 88.794% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -274.548% |
| IXICO plc | 1.9 Million USD | -640.53% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 31.452% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 86.38% |
| CSL Limited | 18.62 Billion USD | 99.924% |
| Cellectis S.A. | 249.36 Million USD | 94.357% |